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Glucocorticoids (GCs) are the most important component of
therapy for a number of diseases including combined chemother-
apy of hematological malignancies. However, their application is
strongly restricted by the development of serious side effects as
well as glucocorticoid resistance. Both side effects and resistance
affect child cancer patients more intensively.
Adverse side-effects of glucocorticoid treatment are the result
of glucocorticoid receptor (GR)-mediated gene activation,
while the beneficial anti-inflammatory effects result from
GR-mediated ‘transrepression’. Difference in mechanisms of
therapeutic and side effects of GCs became obvious and selective
glucocorticoid agonists (SEGRA) were developed aiming to sepa-
rate transactivation from transrepression. Recently we have
demonstrated that one of the modern SEGRAs, 2-(4-acetoxyphenyl)-
2-chloro-N-methyl-ethylammonium chloride or CpdA, selectively
induces transrepression in lymphoma cells and reveals GR-
dependent anti-lymphoma activity in vitro and in vivo. However,
CpdA is a chiral molecule and exists as a racemic mixture of two
enantiomers. Enantiomers often possess the same physical and
chemical properties but their biological effects may differ drastically.
They differently interact with cell receptors and it can lead to the
essential diversity in pharmacokinetics and pharmacodynamics.
The notorious example of such a molecule is Thalidomide which
was originally designed and used as a sedative drug during the preg-
nancy, but it was withdrawn chiefly because of its severe terato-
genicity. As it was demonstrated, only (R)-thalidomide exhibited
significant sedative effects, while (S)-thalidomide revealed the ter-
atogenic effects. The application of enantiopure compounds may
lead to reduction of metabolism variability in patients and to
decrease of drug effective dose. Thereby, the synthesis of enantiop-
ure isomers of CpdA and the study of their anti-cancer activity are of
immediate interest in cancer research.
We synthesized for the first time enantiomers of the CpdA
based on literature precedent Sharpless asymmetric dihydroxyla-
tion with AD-mix-alpha or AD-mix-beta. (S)- and (R)-enantiomers
with enantiopure excess of 98% were obtained. Then we evalu-
ated the cytotoxic effects on acute lymphoblastic leukemia cells
CEM and mantle cell lymphoma cells Granta by direct cell count-
ing and found that cytotoxic activities of both enantiomers were
comparable with the effect of racemic mixture on cell growth and
survival. Glucocorticoids modulate the expression of genes
through transrepression and transactivation mechanisms
realized in equal measure. In present work we estimated the
potential ability of newly synthesized enantiomers to activate
these mechanisms.
Transactivation realizes through direct binding of receptor
homodimers to specific sequences (glucocorticoid responsive ele-
ments (GREs)) in promoter or enhancer regions of GR target genes.
Therefore, we studied the level of transactivation as the expres-
sion of GR-regulated genes, immunophiline FKBP51 and
glucocorticoid-induced leucine zipper GILZ. As shown by Q-RT-
PCR, the expression of FKBP51 and GILZ was unaffected after cell
treatment by both CpdA enantiomers; hence, these compounds
did not induce GR transactivation.
GR-transrepression is chiefly mediated by protein–protein
interaction between GR and other transcription factors like NF-
kB and AP1, followed by inhibition of their transcriptional activity.
We evaluated the transrepression by expression of NF-kB-
depended genes, cyclines D1 and D2 (CCND and CCND2).
(S)-enantiomer of CpdA down-regulated the expression of CCND1
and CCND2 to the level compared with Dex while (R)-enantiomer
surprisingly increased level of CCND1 and CCND2 expression.
This fact demonstrated that (S)-CpdA is perspective as
antiproliferative and cell growth inhibiting agent.
Overall, our data provide the potential for further studies of
CpdA optical isomers, especially (S)-enantiomer, as GR-
dependent anti-cancer agents.
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The expression features of CD20 B-cells in gastric cancer (GC)
are not well understood. The aim of the study was to give
morphological characteristics of CD20 tumor infiltrating
B-lymphocytes (TIL) and evaluate their clinical significance.
We studied the samples of gastric mucosa (GM) adjacent to
tumor in 35 patients with gastric cancer who had undergone rad-
ical surgery (R0) in Orenburg Regional Clinical Oncology Center
between January 2009 and July 2010. The sections were stained
immunohistochemically using antibodies to CD20. The density
of CD20 B-lymphocytes was calculated using the relative area unit
(RAU) equal to 0.42  0.28 mm2 with the magnification400.
We observed 3 types of structures in which the expression of
CD20 B lymphocytes was analyzed: individual cells located dif-
fusely in the GM and the tumor stroma, focal lymphoid infiltrates
(LI) and lymphoid follicles (LF). Cells expressing CD20 were of 2
types: round shape with sharp profile and a narrow rim of cyto-
plasm and irregularly shaped cells with indistinct contours and
lots of cytoplasmic processes. There were 8 patients with atypical
marked LF germinal center (AGC) arranged around the periphery
of the follicle and irregularly shaped. AGC cells had large bright
nucleus of round shape with distinct chromatin clumps and did
not express CD20.
Correlation between density of CD20 B-lymphocyte in GM and
depth of tumor invasion (gamma = 0.474, p = 0.01) and the num-
ber of lymph node metastases was found (gamma = 0.603,
p = 0.008). The lowest density value of CD20 B-lymphocytes was
observed in three or more metastases (N2) in lymph node
(56 + 19.5 + 30.3 + 16.4 and 26.9 + 16.1 cells per unit of area,
respectively, with N0, N1 and N2, p = 0.003) and depth of invasion
G3-4 (55.7 + 19.7 and 32.8 + 19.7 cells per unit of area, respectively,
for G1-2 and G3-4, p = 0.02).
In turn, the presence of focal LI correlated with the degree of
differentiation (gamma = 0.525, p = 0.02) and three-year overall
survival (gamma = 0.738, p = 0.03); the presence of LF correlated
with the Grade (gamma = 0.525, p = 0.02), histological type
(gamma = 0.600, p = 0.03) and the three-year relapse-free survival
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(gamma = 0.636, p = 0.04); the presence of LF with AGC – with
the Grade (gamma = 0.530, p = 0.03), histological type
(gamma = 0.726, p = 0.02) and the degree of dysplasia GM
(gamma = 0.833, p = 0.001). Multiple LF, focal LI and LF with AGC
bit more often observed at grade G3-4 and signet ring cell carci-
noma (SRCC) (LF 0%, 25%, 42.9% and 55.6%, p = 0.23, LI in50%,
42.9%, 100%, 66.7%, p = 0.07 and LF with AGC 12.5%, 0%, 50%,
28.6%, p = 0.17, respectively, when G1 , G2, G3-4 and SRCC) and
diffuse type gastric cancer (LF 20% and 50%, p = 0.12 in 60% and
81.2%, p = 0.23 and LF with AGC 10% and 41.2%, p = 0.07, respec-
tively, for the intestinal and diffuse type gastric cancer). Focal LI
and LF with AGC were more common in moderate and severe
dysplasia of the gastric epithelium (LI 58.3% and 84.6%, p = 0.14
and LF with AGC 50%, 8.3%, p = 0. 02).
A decrease in the three-year relapse-free survival in multiple
LF from 75% to 40%, p = 0.04 and in the presence of focal
LI – 83.3% to 57.9%, p = 0.17 were observed. In the presence of
focal LI, a decrease in the three-year overall survival from 100%
to 73.7% was also observed (p = 0.14).
The findings suggest that B-cells may be associated with the
factors of GC progression. It is important that the high density
of the diffuse B-lymphocytes was typical for early GC, whereas
the presence of LI and multiple LF in GM adjacent to tumor was
more often observed in diffuse type of GC, poorly differentiated
tumors and signet ring cell carcinoma We believed, that further
studies are needed for the understanding of the mechanisms
whereby the B-cell LI and LF may be related with the histology
type and Grade of GC.
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In vitro Epstein-Barr virus (EBV) infects B-cells resulting in
immortalization, In vivo the virus resides latent in resting
B-cells. Rarely the EBV-host cell interaction may contribute to
development of malignant lymphoma. It is well known that both
c-myc translocation and the viral infection are observed in
patients with EBV+ Burkitt’s lymphoma (BL). Proteoglycans (PGs)
are complex glycosylated proteins. They are key components of
ECM and play a critical role in cell–cell and cell–matrix interac-
tions. Disruptions of such interactions will affect B cell interac-
tion with surrounding stroma and may thus perturb the cell
phenotypes. The purpose of this study was to investigate
expressinon of proteoglycans in EBV+ cell lines with different ori-
gins and phenotypes.
We analysed the expression of 12 of the main proteoglycans in
primary B cells, lymphoblastoid cell lines (LCLs) generated by EBV
infection of normal human B cells in vitro and EBV-positive BL cell
lines. An EBV-negative BL cell line was used for reference.
According to RT-PCR analysis, primary B-lymphocytes
expressed different PGs, mainly serglycin, CD44, perlecan and
syndecan-1. The high expression of PGs in normal B cells proba-
bly reflects interactions of these cells with the neighbouring cells
and microenvironment. B cell lines which carry EBV, in general,
showed lower levels of PGs. The PGs expression pattern was sim-
ilar in LCLs and in primary B cells, however, distinguished by high
levels of perlecan and serglycin and low expression of CD44 in
LCLs. BL cells showed the most significant down-regulation of
PGs compared to primary B cells. Therewas a correlation between
the type of EBV latency program, and PGs expression. Serglycin
was expressed at a low levels in BL-cells with EBV latency
III-program compared to LCLs, while in EBV latency I BL cells both
serglycin and perlecan were down-regulated.
Cells with latency I-program show general hypermethylation
of the cellular genome in contrast to cells with latency
III-program. Thus we explored the possibility of epigenetic
regulation of the PG-coding genes by treating cells with
50-deoxyazacytidine (5-AzaC, a demethylating agent) and Tricho-
statin A (TSA, a chromatin structure modulator). There was no
significant change in PGs expression upon this treatment in LCLs
or in EBV latency III BL cells, while EBV latency I BL cells showed
up-regulation of several PGs. This suggests that PGs expression is
at least partly regulated by epigenetic mechanisms. Interestingly
EBV latency is also partly regulated at the epigenetic level.
Similar trends were observed for the key ECM components
(collagen 1A1, fibronectin and elastin). Normal B lymphocytes
expressed collagen, fibronectin and elastin, whereas LCLs and
BL cells showed no expression of these. Treatment of these cells
with 5-AzaC or TSA resulted in similar changes in PGs expression
patterns. Up-regulation of ECM components was detected only in
EBV latency I BL cells.
Taken together, our data show that proteoglycans are
expressed in primary B lymphocytes whereas they are not or only
partly expressed in EBV-carrying cell lines, depending on their
latency program. Expression of PGs in latency I BL cells is silenced
due to hypermethylation, but by another mechanim in latency III
BL cells. These results show that PGs expression patterns follow
the EBV latency programs . It will be highly interesting to further
investigate if EBV and its transformation associated genes are
directly involved in control of PGs, as well as how PGs may con-
tribute to major phenotypic properties of EBV-carrying cell lines,
such as adhesion, migration and growth in soft agarose – a prop-
erty associated with the malignant phenotype of BLs.
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